Influence of febuxostat and allopurinol on renal function for hyperuricemia

Influence of febuxostat and allopurinol on renal function for hyperuricemia - Influence of afebuxostat and allopurinol on renal function for hyperuricemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005964

Enrollment

140

Registered

2011-07-11

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemic patients (Uric acid&gt

Interventions

Febuxostat group: The patients was treated by 10 mg/day of febuxostat and controlled Uric acid less than 6mg/dl/ (maximum 60 mg/day of febuxostat) Allopurinol group: The patients was treated by 100 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Serum Uric acid>8.0mg/dl Patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: The patients who are contraindicated to use febuxostat or allopurinol. Patients who do not agree and whom physician judges inappropriate to this trial for any reason

Design outcomes

Primary

Measure	Time frame
1) Serum uric acid 2) Urinary Albumin	—

Secondary

Measure	Time frame
1) serum Cr 2) eGFR 3) cystatin C 4) Oxidized LDL 5) T-cho, TG, LDL,HDL 6)PWV 7)BNP, EF, LVM 8) side effects	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026